BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Letairis (Ambrisentan) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Letairis (Ambrisentan)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07030894-513@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Letairis (Ambrisentan): Phase 4 readout est. (NCT07030894)
DESCRIPTION:Letairis (Ambrisentan)\, phase 4.\nStudy: Nefecon and Ambrisent
 an in IgA Nephropathy\nEstimated primary completion: 31 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/ambrisentan#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07030894
URL:https://assetmemo.bio/drug/ambrisentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06987097-513@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Letairis (Ambrisentan): Phase na readout est. (NCT06987097)
DESCRIPTION:Letairis (Ambrisentan)\, phase na\, Pulmonary Arterial Hyperten
 sion.\nStudy: Ambrisentan for Early Low-Risk Pulmonary Arterial Hypertensi
 on\nEstimated primary completion: 28 February 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ambrisentan#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06987097
URL:https://assetmemo.bio/drug/ambrisentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06968962-513@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Letairis (Ambrisentan): Phase na readout est. (NCT06968962)
DESCRIPTION:Letairis (Ambrisentan)\, phase na\, Pulmonary Arterial Hyperten
 sion.\nStudy: Comparison of Sequential to Initial Combination Therapy in P
 AH\nEstimated primary completion: May 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/ambrisentan#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT06968962
URL:https://assetmemo.bio/drug/ambrisentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07245680-513@assetmemo.bio
DTSTAMP:20261121T005709Z
DTSTART;VALUE=DATE:20290214
DTEND;VALUE=DATE:20290215
SUMMARY:Letairis (Ambrisentan): Phase 3 readout est. (NCT07245680)
DESCRIPTION:Letairis (Ambrisentan)\, phase 3\, Pulmonary Arterial Hypertens
 ion.\nStudy: COMMODITIES Trial: Initial Dual Oral Therapy vs Monotherapy i
 n PAH With Cardiovascular Comorbidities\nEstimated primary completion: 14 
 February 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ambris
 entan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07245680
URL:https://assetmemo.bio/drug/ambrisentan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
